Solid plans for CDK9

Why inhibiting CDK9 could have broader potential than previously thought

A team led by Temple University scientists has shed light on a new epigenetic mechanism behind a known cancer target, cyclin dependent kinase 9 (CDK9), that may broaden the scope of CDK9 inhibitors to include solid tumors. The team plans to

Read the full 414 word article

User Sign In